# OnCo record a-brave (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/a-brave/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "a-brave", "NCT02926196" ;
  schema:name "A-BRAVE"@en ;
  schema:alternateName "A-Brave"@en ;
  schema:description "A-BRAVE tested a year of the immunotherapy avelumab after standard treatment for high-risk triple-negative breast cancer at Italian and eight British hospitals. Relapse-free survival, the main endpoint, was not significantly improved; a later analysis found the benefit concentrated in tumours rich in immune cells."@en ;
  schema:url <https://onco.cc/trials/a-brave/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02926196>, <https://doi.org/10.1158/1078-0432.CCR-26-0975> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/avelumab/> ;
  onco:terms <https://onco.cc/terms/tils/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/efs/> ;
  onco:trials <https://onco.cc/trials/impassion030/>, <https://onco.cc/trials/swog-s1418/>, <https://onco.cc/trials/keynote-522/> .